CORDIS
EU research results

CORDIS

English EN

Understanding and combating human age-related muscle weakness

Objective

Ageing of skeletal muscle results in a progressive loss of mobility that decreases the quality of life and has major economic and social consequences for society at large. Increasing muscle weakness is a major component of muscle ageing. In the elderly muscles become atrophic (loss in muscle mass) and weaker (loss in muscle force), more susceptible to damage and consequently regenerate and recover more slowly than was the case in their youth. The challenge for FP7 is to identify the relative importance of sarcopaenia, thus proposing standards to define healthy ageing in order to identify age-related muscle weakness; secondly to identify molecular pathways which may be targeted to combat normal age related muscle weakness, and thirdly to identify therapeutic strategies to prevent muscle loss and weakness and enhance recovery following injury or immobilisation. The approaches which we will take to understand and combat muscle weakness in the aged population and improve healthspan can be defined in several steps: the collection and collation of data and samples, the assessment of physiological and functional parameters, the understanding of the various biological mechanisms involved, leading through integration to the development of strategies and their translation for the general European population. In order to develop and propose the general public with efficient countermeasures, the consortium will integrate data from genetics and epidemiology, molecular and cellular biology, physiology, biomechanics, as well as clinical and public health aspects, to ensure optimal scientific synergy from the leading European specialists and companies.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Research Organisations

EU Contribution

€ 1 076 404

Administrative Contact

Mihaja Auguste (Ms.)

Participants (17)

Sort alphabetically

Sort by EU Contribution

Expand all

FONDAZIONE PER LA RICERCA BIOMEDICA AVANZATA ONLUS

Italy

EU Contribution

€ 589 916

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

Italy

EU Contribution

€ 567 516

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 1 079 708

THE MANCHESTER METROPOLITAN UNIVERSITY

United Kingdom

EU Contribution

€ 590 400

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 565 764

UNIVERSITA DEGLI STUDI DI PAVIA

Italy

EU Contribution

€ 288 400

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 664 504

UNIVERSITE DE NAMUR ASBL

Belgium

EU Contribution

€ 556 116

UNIVERSIDAD POMPEU FABRA

Spain

EU Contribution

€ 575 839

UNIVERSITA DEGLI STUDI DI PADOVA

Italy

EU Contribution

€ 834 050

UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

France

EU Contribution

€ 564 640

KAYSER ITALIA SRL

Italy

EU Contribution

€ 523 871

UNILEVER U.K. CENTRAL RESOURCES LIMITED

United Kingdom

EU Contribution

€ 252 766

TARTU ULIKOOL

Estonia

EU Contribution

€ 557 920

JYVASKYLAN YLIOPISTO

Finland

EU Contribution

€ 576 960

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 545 116

INSERM TRANSFERT SA

France

EU Contribution

€ 790 110

Project information

Grant agreement ID: 223576

Status

Closed project

  • Start date

    1 January 2009

  • End date

    30 June 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 14 991 949

  • EU contribution

    € 11 200 000

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France